Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Friday, May 21, 2021

Information

Tags:

Chemical compounds, Pyridines, Tedizolid, Tetrazoles, Fosfomycin, Antibiotic, Infection, Urinary tract infection

Geotags:

King of Prussia, Pa, Us, KENILWORTH, USA, UNITED STATES, IRELAND

Organisation:

NABRIVA THERAPEUTICS US, INC

Summary

Key Points:

b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
Nabriva Therapeutics is also developing CONTEPO\xe2\x84\xa2 (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO\xc2\xae (tedizolid phosphate) in the United States and certain of its territories.\n'

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO^® (tedizolid phosphate) in the United States and certain of its territories.

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
[email protected]

For Media
Andrea Greif
Ogilvy
[email protected]
914-772-3027